Ingredient or product comparison
Comparison: Hair Regrowth Peptides by Research Profile
GHK-Cu (Copper Peptide) VEGF upregulation, angiogenesis around miniaturised follicles 2022 RCT: 33% increase in hair density vs 7% placebo (24 weeks, n=60) Topical 1–2%, daily application Degrades in light/heat; copper binding unstable in poor formulations Hig
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (Copper Peptide)
- VEGF upregulation, angiogenesis around miniaturised follicles
- 2022 RCT: 33% increase in hair density vs 7% placebo (24 weeks, n=60)
- Topical 1–2%, daily application
- Degrades in light/heat; copper binding unstable in poor formulations
- High. Copper chelation efficiency varies 40–80% by synthesis method
- TB-500 (Thymosin Beta-4 Fragment)
- Follicle stem cell migration, actin polymerisation, telogen-to-anagen transition
- 2021 pilot study: 9/12 participants subjective improvement at 12 weeks (no placebo arm)
- Subcutaneous 2–5mg weekly, 8–12 weeks
- Requires injection; limited human data; expensive per dose
- Very high. Fragment sequence must be exact (17-amino-acid chain)
- GHK Tripeptide (No Copper)
- Anti-inflammatory; reduces IL-6, TNF-α suppression of follicle cycling
- 2021 trial: 40% reduction in scalp inflammation markers at 16 weeks
- Topical 0.5–2%, daily application
- Indirect effect; doesn't stimulate growth factors directly
- Moderate. Simpler synthesis but still requires proper folding
- BPC-157 (Off-Label)
- Angiogenesis, wound healing
- No published hair loss trials; mechanism plausible but unproven
- Speculative dosing from wound protocols
- Zero clinical evidence for follicles; purely theoretical
- Low. No validated hair regrowth protocol exists